Clinical trials: Recurrent Prostate Cancer, open to volunteers
Oligometastatic Prostate Cancer (OMPC)
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary…
- Trial name
- PSMA-DC (NCT05939414)
- Testing
- AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
- Where
- 144 sites in United States, Argentina and 25 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy)
Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
Study Overview This research compares two types of post-operative salvage radiotherapy (SRT) for men with prostate cancer who have had surgery but show signs of recurrence (detectable PSA).
- Conditions
- Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostatic Neoplasms
- Trial name
- HYP-OP-RT (NCT07483658)
- Testing
- Standard Fractionation Post-Operative Salvage Radiotherapy (25 fractions), Hypofractionated Post-Operative Salvage Radiotherapy (20 fractions), Androgen Deprivation Therapy (ADT)
- Where
- 4 sites in Canada
- Volunteers
- 434 people
- Sponsor
- CHU de Quebec-Universite Laval
Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
This phase III/IV trial compares the impact of leuprolide and abiraterone acetate (AA) versus relugolix and AA on the heart in hormone-naive patients with advanced prostate cancer receiving pelvic radiation therapy.
- Conditions
- Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT06650579
- Testing
- Abiraterone Acetate, Bicalutamide, Biospecimen Collection
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Emory University
Prostate Cancer, Biochemical Recurrence
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with…
- Trial name
- NCT05753566
- Testing
- Rezvilutamide, Androgen deprivation therapy (ADT), SRT
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Intraprostatic Prostate Cancer
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
The purpose of this study is to assess the impact of prostate-specific membrane antigen/positron emission tomography (PSMA/PET)-informed magnetic resonance (MR)-guided radiation therapy on serious toxicity outcomes in patients…
- Trial name
- NCT07142967
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Androgen Deprivation Therapy (ADT)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- NYU Langone Health
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent
- Trial name
- Fezo-ADT (NCT06957691)
- Testing
- fezolinetant - reference formulation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shehzad Basaria, M.D.
Locally Recurrent Prostate Cancer
Focal Radiotherapy for Previously Treated Prostate Cancer Patients
To examine the feasibility, safety and toxicity of focal stereotactic radiation treatment (SBRT) for locally recurrent prostate cancer.
- Trial name
- NCT03073278
- Testing
- Stereotactic Body Radiotherapy
- Where
- Australia
- Volunteers
- 36 people
- Sponsor
- Royal North Shore Hospital
Prostate Cancer
Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy.
This is a a randomized phase II/III trial comparing salvage SBRT with standard of care (SOC) regimens for patients with a persistent detectable PSA or biochemical progression during follow-up after radical prostatectomy.
- Trial name
- STEREOBED (NCT06523634)
- Testing
- Stereotactic body radiotherapy (SBRT), SOC RT
- Where
- 13 sites in Belgium
- Volunteers
- 284 people
- Sponsor
- Jules Bordet Institute
Prostate Cancer, Prostate Cancer Recurrent
Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities
Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States.
- Conditions
- Prostate Cancer, Prostate Cancer Recurrent, Prostate Metastases
- Trial name
- NCT07690579
- Testing
- Questionnaires, Medical Record Review
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- University of California, San Francisco
Recurrent Prostate Cancer, Prostate Cancer
IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy
Background: Biochemically recurrent prostate cancer (BCR) occurs when prostate-specific antigen (PSA) levels in the blood rise after surgery or radiation. BCR affects 30,000 to 50,000 men each year.
- Trial name
- NCT07686380
- Testing
- N-803, ETBX-71 Vaccine, 18F-DCFPyL
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
PSMA-Guided Surgery and Tissue-Resident T-Cell Profiling in Node-Positive Prostate Cancer
TACTIC-P is a single-center, prospective, single-arm study in 12 men with biopsy-proven prostate cancer and pelvic lymph-node uptake on preoperative PSMA PET, without bone or visceral metastases, who are scheduled for…
- Trial name
- TACTIC-P (NCT07879820)
- Testing
- PSMA-Radioguided Robot-Assisted Radical Prostatectomy With Extended Pelvic Lymph-Node Dissection
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Niguarda Hospital
Prostatic Neoplasms, Prostate Cancer
Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study
This study aims to evaluate the diagnostic performance of [68Ga]Ga-OncoACP3 PET imaging, which targets prostate acid phosphatase (ACP3), in men with clinically suspected or confirmed high-risk prostate cancer, or suspected…
- Trial name
- NCT07830212
- Testing
- [68Ga]Ga-OncoACP3
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yong He
Prostate Cancer, Biochemical Recurrence
Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy
Patients with a biochemical recurrence after radical prostatectomy for moderate- or high- risk prostate cancer are randomly assigned to hypofractionated, accelerated high dose radiation therapy group (65 Gy, 26 fractions) and a…
- Conditions
- Prostate Cancer, Biochemical Recurrence, Radiation, Hypofractionation
- Trial name
- SHARE (NCT03920033)
- Testing
- Salvage radiation therapy
- Where
- 2 sites in South Korea
- Volunteers
- 288 people
- Sponsor
- Asan Medical Center
High Risk Biochemical Recurrence (BCR), Deutenzalutamide Soft Capsules
A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer
This is a multicenter, randomized, double- blind, placebo-controlled Phase III trial to evaluate the efficacy and safety of Deutenzalutamide plus ADT versus placebo plus ADT in patients with high-risk biochemical recurrence (BCR)…
- Trial name
- NCT07875881
- Testing
- Deutenzalutamide Soft Capsules + ADT
- Where
- 3 sites in China
- Volunteers
- 1,044 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Prostate Cancer, Biochemical Relapse Fo Malignant Neoplasm of Prostate
PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE
This observational study was designed to evaluate progression free survival after PSMA-PET/CT based salvage approach for patients affected by biochemical relapse after radical prostatectomy.
- Conditions
- Prostate Cancer, Biochemical Relapse Fo Malignant Neoplasm of Prostate, Prostate Adenocarcinoma, Prostate Cancer Recurrent
- Trial name
- PSICHE (NCT05022914)
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Localized Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
This early phase I is to find out how common vitamin D insufficiency is among African American patients with a history of prostate cancer that has not spread to other parts of the body (localized) or has spread to other places in…
- Conditions
- Localized Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Locally Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
- Trial name
- NCT05045066
- Testing
- Cholecalciferol, Quality-of-Life Assessment, Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Recurrent Adenocarcinoma
Jump: MR Simulation For Radiation Therapy Master Protocol
This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.
- Conditions
- Prostate Cancer, Recurrent Adenocarcinoma, Liver Cancer, Head and Neck Cancer
- Trial name
- JUMP (NCT04545957)
- Testing
- MRI Simulator, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer
Focal Salvage Brachytherapy Study (FocaSaBra)
The aim of this prospective phase II study is to evaluate the toxicity of salvage partial (focal) prostate brachytherapy in patients after prior radiotherapy (standard teleradiotherapy with / without brachytherapy…
- Trial name
- FocaSaBra (NCT05715502)
- Testing
- brachytherapy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- The Greater Poland Cancer Centre
Prostate Cancer, PET/CT
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent [18F]AlF-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of…
- Trial name
- NCT06756334
- Testing
- [18F]AlF-PSMA-N5, [18F]F-DCFPyL
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Prostate Cancer (Post Prostatectomy)
Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy
Prostate cancer patients with high-risk features who undergo radical prostatectomy (RP) are at a significant risk of biochemical recurrence (BCR) and disease progression.
- Trial name
- ARMOR (NCT07711314)
- Testing
- Rezvilutamide Tablets
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School